Treatment of hyperlipidemia in primary practise in Germany: Sub-group analyses from the 4E-registry with particular emphasis on men and women with diabetes mellitus

Experimental and Clinical Endocrinology and Diabetes

Volumn 115, Issue 2, 2007, Pages 85-91

  Assmann, G ^a   Schulte, H ^a   Cullen, P ^a   Neiss, A ^c   Bestehorn, K ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b MSD Sharp and Dohme GmbH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cardiovascular incidences; Cardiovascular risk management; Coronary artery disease

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT RESPONSE;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; FEMALE; GERMANY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIPIDS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PRIMARY HEALTH CARE; REGISTRIES; TREATMENT OUTCOME;

EID: 33947130279     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-955094     Document Type: Article

References (30)

1. Adult Treatment Panel III. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421
2. Assman G, Benecke H, Neiss A, Cullen P, Schulte H, Bestehorn K: Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-registry (Efficacy Calculation and Measurements of Cardiovascular and Cerebrovascular Events including Physician's Experience and Evaluation. European Journal of Cardiovascular Risk and Rehabilitation 2006, (in press)
3. Assmann G, Buyken A, Cullen P, Schulte H, von Eckardstein A, Wahrburg U: Pocket guide to prevention of coronary heart disease 2003. Börm Bruckmeier Verlag, Grünwald, Germany
4. Assmann G, Carmena R, Cullen P et al: Coronary heart disease: reducing the risk. The scientific background for the primary and secondary prevention of coronary heart disease. A worldwide view. Nutrition Metabolism And Cardiovascular Disease 1998; 8: 205-271
5. Assmann G, Cullen P, Schulte H: Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002; 105: 310-315
6. Baigent C, Keech A, Kearney PM et al: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278
7. Barrett-Connor EL, Cohn BA, Wingard DL, Edelstein SL: Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. JAMA 1991; 265: 627-631
8. Becker A, Bos G, de Vegt F et al: Cardiovascular events in type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease. 10-year follow-up of the Hoorn Study. Eur Heart J 2003; 24: 1406-1413
9. Cho E, Rimm EB, Stampfer MJ, Willett WC, Hu FB: The impact of diabetes mellitus and prior myocardial infarction on mortality from all causes and from coronary heart disease in men. J Am Coll Cardiol 2002; 40: 954-960
10. Colhoun HM, Betteridge DJ, Durrington PN et al: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696
11. Collins R, Armitage J, Parish S, Sleigh P, Peto R: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016
12. De Backer G, Ambrosioni E, Borch-Johnsen K et al: European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Atherosclerosis 2004; 173: 381-391
13. De Backer G, Ambrosioni E, Borch-Johnsen K et al: European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 1601-1610
14. Eberly LE, Cohen JD, Prineas R, Yang L: Impact of incident diabetes and incident nonfatal cardiovascular disease on 18-year mortality: the multiple risk factor intervention trial experience. Diabetes Care 2003; 26: 848-854
15. Euroaspire Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001a; 357: 995-1001
16. Euroaspire Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001b; 22: 554-572
17. Evans JM, Wang J, Morris AD: Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ 2002; 324: 939-942
18. Fornengo P, Bruno G, De Salvia A, Arcari R, Pisu E, Pagano G: Low adherence of General Practitioners to National Cholesterol Education Program guidelines for the management of hyperlipidaemia. Diabetes Nutr Metab 2000; 13: 263-268
19. Haffner SM, Lehto S, Ronnemaa T, Pyörälä K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New Engl J Med 1998; 339: 229-234
20. Howard BV, Best LG, Galloway JM et al: Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care 2006; 29: 391-397
21. Hu FB, Stampfer MJ, Solomon CG et al: The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med 2001; 161: 1717-1723
22. Huxley R, Barzi F, Woodward M: Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006; 332: 73-78
23. Lee CD, Folsom AR, Pankow JS, Brancati FL: Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation 2004; 109: 855-860
24. Lotufo PA, Gaziano JM, Chae CU et al: Diabetes and all-cause and coronary heart disease mortality among US male physicians. Arch Intern Med 2001; 161: 242-247
25. Malmberg K, Yusuf S, Gerstein HC et al: Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000; 102: 1014-1019
26. Pajunen P, Koukkunen H, Ketonen M et al: Myocardial infarction in diabetic and non-diabetic persons with and without prior myocardial infarction: the FINAMI Study. Diabetologia 2005; 48: 2519-2524
27. Simons LA, Simons J: Diabetes and coronary heart disease. N Engl J Med 1998; 339: 1714-1715
28. Straka RJ, Taheri R, Cooper SL, Tan AW, Smith AC: Assessment of hypercholesterolemia control in a managed care organization. Pharmacotherapy 2001; 21: 818-827
29. Turnbull F: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527-1535
30. Whiteley L, Padmanabhan S, Hole D, Isles C: Should diabetes be considered a coronary heart disease risk equivalent?: results from 25 years of follow-up in the Renfrew and Paisley survey. Diabetes Care 2005; 28: 1588-1593